Vaccines Market Research Reports & Industry Analysis
Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements of the 20th century. Key issues in the global vaccine market today include unequal access to vaccines, supply chain disruptions, the use of vaccines to prevent pandemics and address bioterrorism, technological innovations, and vaccine hesitancy. Learn more about this critical field with the comprehensive selection of vaccine market research reports available on MarketResearch.com.
New Vaccines Market Data and Insights
- Find data on vaccine market size segmented by region, technology, distribution channel, type, route of administration, and disease.
- Gain a deep understanding of vaccine industry dynamics, market structure, growth outlook, and competitive landscape.
- Learn about influential government initiatives and new vaccination technologies that have highly promising results.
Your Source for Expert Data and Analysis
MarketResearch.com is a trusted research partner, backed by over two decades of experience. Our clients include top investment banks, management consulting firms, and leading multinational companies within the Fortune 500. Our team of research specialists is dedicated to guiding you at every step, ensuring you have the resources and insights you need to answer your toughest research questions. Browse our full list of vaccines industry reports today.
Vaccines Industry Research & Market Reports
-
Allergy Vaccines
... CAGR of 6.0% over the analysis period 2024-2030. Allergic Asthma Type, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$472.1 Million by the end of the ... Read More
-
Subunit Vaccines
... CAGR of 10.1% over the analysis period 2024-2030. Protein Antigen, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Pertussis Vaccines
... CAGR of 4.5% over the analysis period 2024-2030. DTaP Vaccine, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.7 Billion by the end of the analysis ... Read More
-
Nasal Vaccines
... CAGR of 7.2% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$190.5 Million by the end of the ... Read More
-
Ebola Virus Vaccines
... at a CAGR of 6.1% over the analysis period 2024-2030. cAd3-ZEBOV, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$198.9 Million by the end of the ... Read More
-
Dendritic Cell Cancer Vaccines
... 2030, growing at a CAGR of 13.0% over the analysis period 2024-2030. Sipuleucel-T Vaccines, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$987.7 Million by the ... Read More
-
Porcine Vaccines
... CAGR of 4.9% over the analysis period 2024-2030. Inactivated Vaccines Technology, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Veterinary Vaccines
... CAGR of 5.6% over the analysis period 2024-2030. Porcine Vaccines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$4.7 Billion by the end of the analysis ... Read More
-
Fish Vaccines
... CAGR of 8.0% over the analysis period 2024-2030. Killed Vaccine, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$183.0 Million by the end of the analysis ... Read More
-
Pediatric Drugs and Vaccines
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Conjugate, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$52.0 Billion by the end ... Read More
-
Influenza Vaccines
... CAGR of 5.8% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$7.4 Billion by the end of the analysis period. ... Read More
-
Companion Animal Vaccines
... at a CAGR of 5.6% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.5 Billion by the end ... Read More
-
Rubella Vaccines
... CAGR of 2.9% over the analysis period 2024-2030. Monovalent Formulation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$95.3 Million by the end of the analysis ... Read More
-
Malaria Vaccines
... CAGR of 20.0% over the analysis period 2024-2030. Pre-Erythrocytic, one of the segments analyzed in the report, is expected to record a 20.9% CAGR and reach US$4.1 Billion by the end of the analysis period. ... Read More
-
Human Papillomavirus (HPV) Vaccines
... 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Tetravalent, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$5.8 Billion by the end ... Read More
-
DNA Vaccines
... CAGR of 6.2% over the analysis period 2024-2030. Oncept, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$445.9 Million by the end of the analysis period. ... Read More
-
Adult Vaccines
... CAGR of 5.2% over the analysis period 2024-2030. Live Attenuated, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$6.9 Billion by the end of the analysis ... Read More
-
Inactivated Vaccines
... CAGR of 4.5% over the analysis period 2024-2030. Viral Vaccine Type, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$35.3 Billion by the end of the ... Read More
-
Livestock Vaccines
... CAGR of 5.0% over the analysis period 2024-2030. Bovine Vaccine, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$2.8 Billion by the end of the analysis ... Read More
-
Digital Vaccines
... CAGR of 9.2% over the analysis period 2024-2030. Smartphones Device, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Meningococcal Vaccines
... CAGR of 4.8% over the analysis period 2024-2030. Quadrivalent, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.1 Billion by the end of the analysis period. ... Read More
-
Global Human Combination Vaccines Market 2025-2029
... combination vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market ... Read More
-
Africa Animal Health Market Report Research Report Information by Animal Type (Animal and Companion Animal), by Product (Pharmaceuticals, Vaccines, Feed Additives, Hygiene Products, and Diagnostics), by Distribution Channel (Retail Pharmacies, E-Commerce, and Others), by Region Industry Forecast to 2032
... feed additives, diagnostics, and medical devices. Antibiotics, anti-parasitic medications, vaccinations against rabies and foot-and-mouth disease, dietary supplements, and veterinary diagnostic equipment are important goods. The worldwide animal health industry is expanding due to rising pet ... Read More
-
Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines)- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
... period from 2024 to 2033. Key Takeaways: The manufacturing segment held the largest share of the global biotechnology contract manufacturing market in 2023. The biologic drug substance manufacturing segment held the largest share of the ... Read More
-
Australia Adjuvants Market- Trend Analysis & Forecasts
... million, with projections estimating it will reach USD ** million by 2030. Adjuvants—used to enhance the performance of herbicides, insecticides, and fungicides—play a critical role in Australia’s broadacre farming, particularly in grain crops like wheat, ... Read More
Research Assistance
